trial · primary record
QL1706 Plus Celecoxib Group
Esophageal Squamous Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 35 |
| Primary completion | 2027-09-01 |
| Primary endpoint | Objective Response Rate (ORR) as assessed by RECIST v1.1 |
| Registry ID | NCT07049185 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:24.885Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07049185
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.